CompletedPhase 2

A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

United States189 participantsStarted 2015-03-10

Plain-language summary

To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Botulinum toxin to the axillary area within 1 year of the baseline visit.
✕. Axillary iontophoresis within 12 weeks of baseline visit.
✕. Axillary thermolysis, sympathectomy or surgical procedures of the axillary area at any time in the past.

What they're measuring

Proportion of Subjects Achieving at Least 2-point Decrease in Hyperhidrosis Disease Severity Scale (HDSS) From Baseline to Week 4

Timeframe: Baseline through Week 4 (Day 29)

Trial details

NCT IDNCT02336503

SponsorBotanix Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-11-05

Results submitted2022-12-14

View on ClinicalTrials.gov More Hyperhidrosis trials